Evidence map›Paper›PMID 36364978›Full record

ReviewPathogens (Basel, Switzerland)2022

Mikaela Coleman, Leonardo Martinez, Grant Theron, Robin Wood, Ben Marais

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Delayed-Type Hypersensitivity toInternational journal of molecular sciences · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Airborne Mycobacterium tuberculosis inactivated by advanced photohydrolysis technology.Annals of clinical microbiology and antimicrobials · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Molecular Epidemiology ofMicroorganisms · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mikaela ColemanWHO Collaborating Centre for Tuberculosis and the Sydney Institute for Infectious Diseases, The University of Sydney, Sydney 2006, Australia.ORCID 0000-0002-4414-5645
Leonardo MartinezDepartment of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA.
Grant TheronDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7602, South Africa.ORCID 0000-0002-9216-2415
Robin WoodDesmond Tutu Health Foundation and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7700, South Africa.
Ben MaraisWHO Collaborating Centre for Tuberculosis and the Sydney Institute for Infectious Diseases, The University of Sydney, Sydney 2006, Australia.

Funding

The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Chad J Achenbach, SALLY Maureen MCFALL · 2018 to 2026
$24.0M
Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)U01AI152087 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA, DENKINGER, CLAUDIA MARIA · 2020 to 2024
$19.3M
HIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0M
Pre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosisR01AI136894 · NIAID · STELLENBOSCH UNIVERSITY · PI THERON, GRANT DE VOS · 2019 to 2023
$678k
Identifying effective and efficient approaches to tuberculosis screening in BrazilianprisonsK01AI156022 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MARTINEZ, LEONARDO · 2021 to 2025
$640k
European Union RIA2018D-2493European Union RIA2018D-2509European Union RIA2020I-3305FIC NIH HHS D43 TW010350Medical Research Future Fund APP1200755NIAID NIH HHS K01 AI156022NIAID NIH HHS R01 AI136894NIAID NIH HHS U01 AI152087NIBIB NIH HHS U54 EB027049NIH HHS 1K01AI156022-01NIH HHS D43TW010350NIH HHS R01AI136894NIH HHS U01AI152087NIH HHS U54EB027049
6 · The paper itself

Abstract

Tuberculosis has affected humankind for thousands of years, but a deeper understanding of its cause and transmission only arose after Robert Koch discovered

Indexed as

COVID-19high-incidencemycobacterium tuberculosisTBtransmission

Identifiers

PMID36364978
PMCPMC9695830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.